Inhibrx, Inc.

NASDAQ
INBXV
paper.types.company
Rentabilité sur six mois: 0%
Rendement en dividendes: 0%
Secteur: Нефтегаз

Calendrier des promotions Inhibrx, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Inhibrx, Inc.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.

plus de détails
It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2024-05-28
Валюта
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 0 0
P/BV 0 0
P/E 0 0
Efficacité
Nom Signification Grade
ROA 0 0
ROE 0 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA 0 10
Debt/Ratio 0 10
Debt/Equity 0 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 0 0
Rentabilité EPS, % 0 0
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 30.85 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 30.85 $ 30.85 $ 30.85 $ 0 % 0 % 0 %
common.calendar.number_days.30d 30.85 $ 30.85 $ 30.85 $ 0 % 0 % 0 %
common.calendar.number_days.90d 30.85 $ 30.85 $ 30.85 $ 0 % 0 % 0 %
common.calendar.number_days.180d 30.85 $ 30.85 $ 30.85 $ 0 % 0 % 0 %
common.calendar.number_days.1y 30.85 $ 30.85 $ 30.85 $ 0 % 0 % 0 %
common.calendar.number_days.3y 0 $ 30.85 $ 31.25 $ 0 % 0 % 0 %
common.calendar.number_days.5y 0 $ 30.85 $ 31.25 $ 0 % 0 % 0 %
common.calendar.number_days.10y 0 $ 30.85 $ 31.25 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 30.85 $ 30.85 $ 30.85 $ 0 % 0 % 0 %

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Mark Paul Lappe Founder, Chairman, President & CEO 1967 (58 années)
Dr. Brendan P. Eckelman Ph.D. Founder & Chief Scientific Officer 1979 (46 années)
Mr. Quinn L. Deveraux Founder
Dr. Ashraf Amanullah Executive VP & Chief Technical Operations Officer 1968 (57 années)
Ms. Leah Pollema J.D. VP, Corporate Secretary & General Counsel
Dr. Charbel Helaihel Pharm.D. Vice President of Marketing & Commercial Planning
Mr. Jeffrey J. Jensen Executive VP & Chief Clinical Operations Officer
Mr. David Matly M.B.A. Executive VP and Chief Commercial & Business Development Officer
Dr. Carlos Bais Ph.D. Executive Vice President of Translational Sciences
Dr. Josep Garcia Ph.D. EVP & Chief Clinical Development Officer

Informations sur l'entreprise

Adresse: United States, La Jolla, 11025 North Torrey Pines Road - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://inhibrx.com